Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 2, 2012
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantationWillemijn Hobo, Kelly Broen, Walter J F M van der Velden, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2014
Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow TransplantationAyad Ahmed Hussein, Constantijn M Halkes, Gérard Socié, et al.
Nature Genetics|June 2, 2009
Acquired mutations in TET2 are common in myelodysplastic syndromesSaskia M C Langemeijer, Roland P Kuiper, Marieke Berends, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 TrialSergio Amadori, Stefan Suciu, Dominik Selleslag, et al.
Haematologica|September 17, 2016
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantationGordon Cook, Simona Iacobelli, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Bone Marrow Transplantation|October 2, 2021
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMTStavroula Masouridi-Levrat, Eduardo Olavarria, Simona Iacobelli, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 2, 2012
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantationWillemijn Hobo, Kelly Broen, Walter J F M van der Velden, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2014
Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow TransplantationAyad Ahmed Hussein, Constantijn M Halkes, Gérard Socié, et al.
Nature Genetics|June 2, 2009
Acquired mutations in TET2 are common in myelodysplastic syndromesSaskia M C Langemeijer, Roland P Kuiper, Marieke Berends, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 TrialSergio Amadori, Stefan Suciu, Dominik Selleslag, et al.
Haematologica|September 17, 2016
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantationGordon Cook, Simona Iacobelli, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Bone Marrow Transplantation|October 2, 2021
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMTStavroula Masouridi-Levrat, Eduardo Olavarria, Simona Iacobelli, et al.
Pageof 16